Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 5 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 2 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
4(80.0%)
Phase 2
1(20.0%)
5Total
Phase 1(4)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (5)

Showing 5 of 5 trials
NCT01047722Phase 1Unknown

In-Vivo Bleeding Volume Test for Platelet-Aspirin Interaction

Role: lead

NCT02503904Phase 2Unknown

Tumescent Antibiotic Delivery for Prevention of Surgical Site Infection

Role: lead

NCT01463280Phase 1Completed

Effect of Tumescent Lidocaine on Platelet Function

Role: lead

NCT01046981Phase 1Completed

Tumescent Antibiotic Delivery Pharmacokinetics

Role: lead

NCT00977028Phase 1Unknown

Tumescent Lidocaine Maximum Safe mg/kg Dosage

Role: lead

All 5 trials loaded